Prostate Cancer Clinical Trial
Official title:
Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Locally Advanced Prostate Cancer and Biomarker Research
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation. It is not yet known if neoadjuvant radiation therapy is a more effective therapy for high-risk prostate cancer. PURPOSE: Two-stage randomized trial to compare the effectiveness and safety of neoadjuvant radiotherapy and hormone therapy followed by radical prostatectomy in men with high-risk locally advanced prostate cancer
Status | Recruiting |
Enrollment | 38 |
Est. completion date | July 1, 2041 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: - Men with age from 20 to 75 years old - Signed an informed consent form (ICF) indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study; subjects must be willing and able to adhere to the prohibitions and restrictions specified in this protocol - Histologically confirmed adenocarcinoma of the prostate - High-risk locally advanced disease defined by =1 of the following 3 criteria: - T3a-3b by DRE or MRI - Gleason score = 8 (= Grade group 4) - PSA =20 ng/ml - Willing to undergo prostatectomy as primary treatment - ECOG Performance status 0 or 1 Exclusion Criteria: - Pathological finding of small cell, ductal or neuroendocrine carcinoma - Current or prior hormone therapy, radiotherapy, or chemotherapy - Evidence of metastasis (M1) on images - Other prior malignancy =5 years prior to enrollment - Any of the following within 6 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated deep vein thrombosis is not considered exclusionary - Human immunodeficiency virus-positive subjects with 1 or more of the following: 1. Not receiving highly active antiretroviral therapy 2. Had a change in antiretroviral therapy within 6 months of the start of screening 3. Receiving antiretroviral therapy that may interfere with study drug (consult sponsor for review of medication prior to enrollment) 4. CD4 count <350 at screening 5. AIDS-defining opportunistic infection within 6 months of start of screening - Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction - History of seizure or any condition that may predispose to seizure (including, but not limited to, prior stroke, transient ischemic attack, or loss of consciousness =1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect) - Gastrointestinal conditions affecting absorption |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital Yunlin Branch | Douliu City/Huwei Township | Yunlin County |
Taiwan | National Taiwan University Hospital | Tapiei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathologic outcome | pathologic complete response (pCR) or pathologic near complete response (minimal residual disease, MRD) rate | From date of randomization to the date of radical prostatectomy, up to 100 weeks | |
Secondary | PSA decline percentage | PSA decline is defined as nadir PSA value/baseline PSA value × 100 | From date of randomization to 10 years | |
Secondary | PSA complete response rate | Complete response is defined as a drop in PSA on protocol treatment to less than 0.2 ng/ml. | From date of randomization to 10 years | |
Secondary | PSA Recurrence | Biochemical recurrence is defined as a rise in PSA to 0.2 ng/mL and a confirmatory value of 0.2 ng/mL or greater following radical prostatectomy | From date of randomization to 10 years | |
Secondary | Distant Failure | Distant failure rate is estimated by the cumulative incidence method, with failure defined as the first occurrence of distant failure. | From date of randomization to 10 years | |
Secondary | Prostate Cancer Death | Prostate cancer death rate us estimated by the cumulative incidence method, with failure defined as death due to prostate cancer or complications of trial. | From date of randomization to 10 years | |
Secondary | Overall Survival | Overall survival is estimated by the Kaplan-Meier method, with failure defined as death by any cause. | From date of randomization to 10 years | |
Secondary | Progression-free Survival | Progress-free survival is estimated by the Kaplan-Meier method, with failure defined as the first occurrence of PSA failure, local, regional or distant failure, or death from any cause. | From date of randomization to 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |